Roth Capital Partners, LLC
888 San Clemente Drive, Suite 400
Newport Beach, CA 92660
VIA EDGAR CORRESPONDENCE
|
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
100 F
Street, N.E.
Washington,
D.C. 20549
|
|
Re:
Tenax
Therapeutics, Inc.
Registration
Statement on Form S-1
File
No. 333-275856
Ladies
and Gentlemen:
Pursuant to Rule
461 of the General Rules and Regulations under the Securities Act
of 1933, as amended (the “Act”), we, the placement
agent, hereby request that the Securities and Exchange Commission
(the “Commission”) take appropriate action to cause the
above-referenced registration statement on Form S-1 (the
“Registration Statement”) to become effective at 5:30
p.m., Eastern time, on Tuesday, February 6, 2024, or as soon
thereafter as practicable.
Pursuant to Rule
460 under the Act, we wish to advise you that we have distributed
as many copies of the Preliminary Prospectus dated February 2, 2024
to agents, dealers, institutions and others as appears to be
reasonable to secure adequate distribution of the preliminary
prospectus.
The
undersigned, as placement agent, has complied and will comply with
Rule 15c2-8 under the Securities Exchange Act of 1934, as
amended.
|
|
Very
truly yours,
ROTH CAPITAL PARTNERS, LLC
By: /s/ Aaron M.
Gurewitz
Aaron M. Gurewitz
President
|
cc:
M. Ali Panjwani,
Esq.
Pryor
Cashman LLP